LifeStance Health Group (NASDAQ:LFST) Announces Earnings Results

LifeStance Health Group (NASDAQ:LFST) posted its quarterly earnings data on Thursday. The company reported $0.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.04 by $0.02, Zacks reports. LifeStance Health Group had a net margin of 4.29% and a return on equity of 4.82%. The firm had revenue of $455.86 million during the quarter, compared to the consensus estimate of $431.59 million. The company’s quarterly revenue was up 25.3% compared to the same quarter last year.

Here are the key takeaways from LifeStance Health Group’s conference call:

• Third-quarter revenue rose 25% to $456 million, driven by 17% growth in visit volume and a 7% increase in revenue per visit. Adjusted EBITDA increased 70% to $68 million, a 15% margin for the second consecutive quarter.
• LifeStance raised its full-year 2026 guidance: revenue to $1.741 billion–$1.761 billion and Adjusted EBITDA to $242 million–$250 million. The midpoint implies 23% revenue growth and roughly 300 basis points of year-over-year margin expansion.
• The clinician base grew 11% to 8,863, with 321 net additions in the quarter; management cited strong recruiting and stable retention. Visits per average clinician rose 5% year over year, which executives attributed partly to improved patient engagement.
• Specialty services revenue is expected to grow about 40% in 2026 to roughly $70 million, with management expecting a similar growth rate next year. The company is gradually expanding TMS and SPRAVATO, while citing positive outcomes data and opportunities to discuss coverage and reimbursement with payers.
• The new EHR rollout is expected to reduce 2027 revenue growth by approximately 1–2 percentage points, putting growth toward the lower end of LifeStance’s long-term mid-teens range. Management also previously estimated implementation costs of $20 million–$30 million; the phased rollout is expected to be completed by year-end 2027.

LifeStance Health Group Price Performance

Shares of LifeStance Health Group stock traded up $0.34 during midday trading on Friday, hitting $13.77. 4,924,487 shares of the company traded hands, compared to its average volume of 3,459,394. The firm’s fifty day moving average price is $12.62 and its 200-day moving average price is $9.49. The stock has a market cap of $5.26 billion, a price-to-earnings ratio of 72.48 and a beta of 1.35. LifeStance Health Group has a 12 month low of $5.87 and a 12 month high of $15.66. The company has a debt-to-equity ratio of 0.17, a quick ratio of 1.38 and a current ratio of 1.44.

Insider Activity at LifeStance Health Group

In other LifeStance Health Group news, COO Lisa Miller sold 47,912 shares of the firm’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $10.85, for a total value of $519,845.20. Following the sale, the chief operating officer owned 281,289 shares in the company, valued at $3,051,985.65. This trade represents a 14.55% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CTO Vukasin Paunovich sold 44,394 shares of the firm’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $10.85, for a total transaction of $481,674.90. Following the completion of the sale, the chief technology officer owned 247,446 shares in the company, valued at $2,684,789.10. This represents a 15.21% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 13,777,580 shares of company stock valued at $146,433,781 in the last quarter. Insiders own 3.50% of the company’s stock.

Analyst Upgrades and Downgrades

LFST has been the topic of a number of recent analyst reports. Weiss Ratings upgraded LifeStance Health Group from a “hold (c-)” rating to a “hold (c)” rating in a research report on Tuesday, August 11th. JPMorgan Chase & Co. increased their price objective on shares of LifeStance Health Group from $9.00 to $13.00 and gave the stock a “neutral” rating in a research note on Friday, August 14th. Canaccord Genuity Group raised their target price on shares of LifeStance Health Group from $15.00 to $16.00 and gave the company a “buy” rating in a report on Friday. Zacks Research cut shares of LifeStance Health Group from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 13th. Finally, Barclays boosted their target price on shares of LifeStance Health Group from $13.00 to $15.00 and gave the company an “overweight” rating in a research report on Thursday, September 10th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $13.75.

Key Stories Impacting LifeStance Health Group

Here are the key news stories impacting LifeStance Health Group this week:

• Positive Sentiment: LifeStance reported Q3 adjusted earnings of $0.06 per share, ahead of estimates, and revenue of $455.9 million versus forecasts of about $431.6 million. Revenue grew 25.3% year over year, and the company raised its full-year outlook—evidence of stronger-than-expected performance. LifeStance Q3 results and outlook
• Positive Sentiment: Analysts raised their targets and maintained bullish ratings: KeyCorp lifted its target to $17 with an “overweight” rating, Canaccord Genuity raised its target to $16 with a “buy” rating, and BTIG increased its target to $20, also with a “buy” rating. These revisions signal greater optimism about potential upside. KeyCorp rating Canaccord Genuity rating BTIG target increase
• Neutral Sentiment: Coverage noted LFST reached a 52-week high and highlighted its momentum, though those signals alone do not establish whether further gains are sustainable. Zacks coverage of LFST’s high

About LifeStance Health Group

LifeStance Health Group, Inc is a provider of outpatient behavioral health services in the United States. Through a network of clinicians and care centers, the company offers mental health care through in-person appointments and telehealth visits.

LifeStance’s services include individual, couples and family therapy; psychiatric evaluation and medication management; psychological and neuropsychological testing; and treatment for conditions such as depression, anxiety, attention-deficit/hyperactivity disorder, bipolar disorder, post-traumatic stress disorder and other behavioral health concerns.